Inhibition of somatostatin receptor 5-signaling by mammalian regulators of G-protein signaling (RGS) in yeast  by Kong, Janice L. et al.
Inhibition of somatostatin receptor 5-signaling by mammalian regulators
of G-protein signaling (RGS) in yeast
Janice L. Kong b;1, Rosemarie Panetta a;1;2, Wei Song a, Wendy Somerville b,
Michael T. Greenwood a;b;*
a Division of Cardiology in the Department of Medicine, McGill University Hospital Center, Montreal, QC, Canada
b Department of Anatomy and Cell Biology, McGill University, Montreal, QC Canada
Received 26 July 2001; received in revised form 1 October 2001; accepted 12 October 2001
Abstract
Regulators of G-protein signaling (RGSs) are negative regulators of G-protein coupled receptor (GPCR)-mediated
signaling that function to limit the lifetime of receptor-activated GK-proteins. Here we show that four mammalian RGSs
differentially inhibit the activation of a FUS1^LacZ reporter gene by the STE2 encoded GPCR in yeast. In order to examine
the role of the GPCR in modulating RGS function, we functionally expressed the human somatostatin receptor 5 (SST5) in
yeast. In the absence of RGSs, FUS1^LacZ activation in response to somatostatin increased in a dose-dependent manner in
cells expressing SST5. In contrast to the results obtained with Ste2p, all RGSs completely inhibited SST5-mediated signaling
even at concentrations of agonist as high as 1035 M. The ability of RGSs to inhibit SST5 signaling was further assessed in
cells expressing modified Gpa1 proteins. Even though SST5-mediated FUS1^LacZ activation was 5-fold more efficient with a
Gpa1p/Gi3K chimera, response to somatostatin was completely abolished by all four RGSs. Furthermore, we demonstrate
that RGS1, RGS2 and RGS5 have reduced ability to inhibit SST5-mediated activation of the RGS-resistant Gpa1pGly302Ser
mutant suggesting that the ability to interact with the GK-protein is required for the inhibition of signaling. Taken together,
our results indicate that RGSs serve as better GAPs for Gpa1p when activated by SST5 than when this G-protein is activated
by Ste2p. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Regulators of G-protein signaling (RGS) are a
family of s 30 mammalian proteins that serve to
negatively regulate G-protein coupled receptor
(GPCR) signaling [1^4]. The overexpression of
RGS containing sequences have been shown to in-
hibit signaling from a large number of di¡erent
GPCRs in both mammalian cell systems and model
organisms such as yeast and Caenorhabditis [1^4].
The term RGS refers to a conserved ca. 120 residue
motif that functionally inactivates the GTP bound
form of the GK-subunit of heterotrimeric G-proteins
[1]. The remaining portions of RGS containing pro-
teins are largely diverse in size and sequence [4]. A
number of RGSs, such as RGS1, RGS2, RGS5 and
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RGS16 are small proteins (ca. 200 residues) that con-
tain very little sequence in addition to their RGS
motif. The non-RGS sequences of the small RGSs
largely contain no discernible sequence identity to
other known proteins; however, they have been
shown to be required for subcellular localization
and function [5^7]. In contrast, there are a number
of large RGS containing proteins, such Axin and
p115RhoGEF, in which the RGS motif makes up
only a small part of the entire protein. The presence
of known sequence motifs, such as PDZ and GGL,
in several of these RGSs suggests that they may have
other specialized functions [8^11]. Very little is cur-
rently known regarding the speci¢city of the small
RGSs with regards to their ability to inactivate the
s 20 di¡erent mammalian GK-proteins. In vitro bio-
chemical assays using a number of di¡erent RGSs
and GK-proteins have suggested that some RGSs dis-
play preferential a⁄nity for certain classes of GK-
proteins [12^14]. For example, RGS2 has been
shown to be highly speci¢c for GqK in vitro [12],
and yet has been shown to function with other
classes of GK proteins, notably GiK, in a reconsti-
tuted lipid vesicle based assay [15]. Whereas no
RGS have been shown to stimulate the GTPase ac-
tivity of GsK in vitro [12,16,17], a number of di¡erent
RGSs, including RGS2 and RGS3T inhibit GsK-
mediated signaling when overexpressed in cultured
cells [18,19]. These results suggest that other cellular
components may be involved in modulating the in
vivo function of small RGSs. Recent reports have
implicated the GPCR itself as playing a role in de-
termining the strength and selectivity of RGS^GK
interactions [20^22]. For example, Harder et al.
have shown that RGS4 but not RGS7, RGS9 or
GAIP, can inhibit both TRH1 and TRH2 receptors
[21] whereas Richardson et al. have reported that
RGS4 inhibited PAF receptor but not the GPCRs
for FR or CXCR [22]. In addition, RGS4 has been
reported to be 4 and 33 times more potent at inhib-
iting carbachol signaling than bombesin or cholecys-
tokinin, respectively [20]. Taken together, these stud-
ies indicate a role for the GPCR in modulating the
function of RGSs. Characterization of the role of the
GPCR in regulating RGS function in mammalian
cells is complicated by the fact that any given cell
expresses multiple GPCRs, GK-proteins and RGSs
[23^25]. Thus the ability of an overexpressed RGS
to inhibit a particular GPCR activated GK-protein
may be limited by the presence of endogenous
RGSs. For example, the yeast RGS containing pro-
tein, Sst2p serves to regulate the Ste2p GPCR for the
mating pheromone K-factor [26^29]. Even though
overexpression of the SST2 gene leads to a decrease
in GPCR-mediated responses, yeast mutants devoid
of their SST2 gene are nevertheless hyperesponsive
to the e¡ects of K-factor. This suggests that although
the basal levels of Sst2p are present in limiting
amounts, it is, nevertheless, su⁄cient to limit the ex-
tent of GPCR-mediated responses.
The pheromone response pathway of the yeast
Saccharomyces cerevisiae is a relatively simple
GPCR-mediated signaling cascade that consists of a
single GPCR (Ste2p), RGS (Sst2p) and GK-protein
(Gpa1p) [29]. Since it has been demonstrated that
mammalian genes can functionally replace yeast
genes in this pathway, it is a widely used model to
study mammalian GPCRs and RGSs [30^35]. We
have therefore used a yeast-based assay to evaluate
the ability of various RGSs to inhibit GPCR-medi-
ated activation of an FUS1^LacZ reporter gene from
two di¡erent receptors. Using this assay, we have
demonstrated that Ste2p-mediated activation of an
FUS1^LacZ reporter gene is di¡erentially inhibited
by four di¡erent mammalian RGSs. In contrast, all
four RGSs completely inhibited FUS1^LacZ report-
er activation-mediated by the heterologously ex-
pressed somatostatin receptor 5 (SST5). These results
suggest that GPCRs are able to in£uence the ability
of RGSs to function as GAPs for Gpa1p.
2. Experimental procedures
2.1. Materials
DNAzol was obtained from Gibco/BRL. Chloro-
phenol red-L-D-galactopyranoside was from Roche
Molecular Biochemicals. Vent and Pfu DNA poly-
merases were respectively obtained from New Eng-
land BioLabs and Stratagene.
2.2. Polymerase chain reaction
PCR was routinely used to amplify cDNAs to fa-
cilitate cloning. PCR reactions using Vent or Pfu
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DNA polymerases were essentially carried out as
previously described [36]. In some cases, 5% DMSO
was added to the PCR reaction to facilitate the de-
naturing of the template DNA. Yeast and human
genomic DNA, used as a template for some PCR
reactions, were isolated using DNAzol essentially as
described by the manufacturer. Sequence analysis
con¢rmed the absence of mutations in the clones
ampli¢ed by PCR.
2.3. RGS expressing plasmids
PCR products of the coding sequence of human
(h) RGS1, mouse (m) RGS2, hRGS5 and hRGS16
modi¢ed to contain the yeast Kozak sequence
were previously described [33]. All four RGSs were
individually subcloned as BamHI^SalI fragments
from the polylinker of p423GAL1 into the poly-
linkers of both p426MET25 and p427MET25 [37].
p427MET25 was constructed by replacing the
URA3 gene in p426MET25 with the LYS2 gene us-
ing an in vivo recombination methodology [38].
Brie£y, a 4.7-kb PCR fragment containing the entire
LYS2 gene was ampli¢ed using PCR with the follow-
ing forward 5P-GGAGTTAGTTGAAGCATTAG-
GTCCCAAAATTTGTTTACTAAAAAAGGGAA-
CAAAAGCTGGGTACCGGGCCCCCCCTCGAG-
GTCG-3P and reverse 5P-TATGCTTCCCAGCC-
TGCTTTTCTGTAACGTTCACCCTCTACCATT-
TACAGTTCTTATTCAATAACTAATATTTTAT-
TCTCTTAT-3P primers using pDP6 as a template.
The 5P- and 3P-end of the oligonucleotides contain
sequences found within the 5P- and 3P-ends of the
URA3 gene on p426MET25. This LYS2 fragment
was co-transformed into the yeast strain RP2L along
with p426MET25 that was linearized within the
URA3 coding sequence with ApaI. Homologous re-
combination of the LYS2 PCR fragment into the
URA3 gene served to generate p427MET25.
2.4. GPCR expressing plasmids
The coding sequences of mammalian GPCRs were
ampli¢ed by PCR using the following oligonucleoti-
des and cloned cDNAs as templates: EP4 receptor:
pcDNA3-hEP4, forward: 5P-GAACTAGTCAAA-
CAATGTCCACTCCCGGGGTCAATTCG-3P and
reverse: 5P-GAGTCGACCCTTGCCTATTATATA-
CATTTTTCTG-3P ; hEP3K6ÿ1 receptor: pcDNA3-
hEP3K6ÿ1, forward: 5P-GAACTAGTCAAACAATG-
AAGGAGACCCGGGGCTACGGA-3P reverse: 5P-
GAGTCGACTGTCCAACTCCGTTCTTTTCA-3P ;
hFP receptor: pcDNA-hFP forward: 5P-GACCCG-
GGCAAACAATGTCCATGAACAATTCCAAAC-
AG-3P reverse: 5P-GAGTCGACCAGATTTACTG-
TCCTATTAAGCTA-3P ; hL2AR receptor: pUC18-
hL2AR (ATCC# 57537) forward: 5P-CTGGATCC-
CAAACAATGGGGCAACCCGGGAACGGC and
reverse: 5P-CTGTCGACGCTTTACCAGCAGTA-
GTCATTTGTACTACA-3P rat (r) AT1 receptor:
forward: 5P-CTGGATCCCAAACAATGGCCCT-
TAACTCTTCTGCT-3P and reverse: 5P-CTGTCG-
ACTCACTCCACCTCAAAACAAGAC-3P. The hu-
man SST5 receptor was ampli¢ed from genomic
DNA using the following forward 5P-GAAAGCTT-
CAAACAATGGAGCCCCTGTTCCCAGCCTCC-
3P and reverse 5P-GAGTCGACTCACAGCTTGC-
TGGTCTGCATAAGCCC-3P oligonucleotides. The
GPCR PCR products were ¢rst cloned into pBlue-
script (Stratagene) and subsequently cloned into
p426MET25 as SmaI^SalI or SpeI^SalI fragments.
2.5. GPA1 expressing plasmids
A 1.6-kb genomic fragment containing the entire
coding sequence of the GPA1 gene as well as 200 bp
of 5P-non-coding sequence was ampli¢ed by PCR
from yeast DNA using the following GPA1 for-
ward 5P-CAGAGCTCGAGGATAGTAGAATTC-
CACCA-3P and GPA1 reverse 5P-CTGGATCCAA-
TTATACAGTTCCTTCATATAATAC-3P oligonu-
cleotide primers. A 5P-SacI restriction site as well
as a 3P-BamHI restriction site were introduced into
the GPA1 fragment to facilitate cloning. The yeast
expression vector p414GALS was digested with SacI
and BamHI to remove the GALS promoter and to
clone the SacI^BamHI GPA1 fragment. The resul-
tant plasmid p414GPA1 will express the GPA1
gene under its endogenous promoter and be main-
tained at ca. 1 copy per cell thereby allowing it to
mimic the endogenous levels of Gpa1p expected in
wild type cells in yeast mutants lacking their endog-
enous GPA1 gene [32]. PCR mutagenesis was used to
replace the 5 C-terminal codons of GPA1 with the
corresponding sequence from mammalian Gi3K to
make the GPA1/Gi3K transplant mutant [32]. This
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was accomplished by re-amplifying the cloned GPA1
gene using the forward primer described for GPA1
and the following reverse primer 5P-GAGTCGA-
CCTTCAGTACAAACCACATTCTTTAAGGTTT-
TGCTGGATGATTAGATCGGTG-3P. The GPA1/
G i3K fragment was also cloned into the yeast expres-
sion vector p414GALS but as a BamHI^SalI frag-
ment since there is a SalI restriction site in the GPA1/
Gi3K reverse primer.
A 2-step PCR mutagenesis approach was used to
construct the GPA1Ser302Gly mutant [36,39]. GPA1
was ¢rst ampli¢ed as 2 separate but overlapping
fragments; the 5P-fragment using the GPA1 forward
oligo and the mutant GPA1 reverse oligo 5P-
AAATTCGGTTTCTGTAATCGATGTAGTCTT-
TATACGGCC-3P and the 3P-fragment was ampli¢ed
using the GPA1 reverse oligonucleotide and the mu-
tant forward oligonucleotide 5P-GGCCGTATAAA-
GACTACATTCGATTACAGAAACCTTT-3P. The
Ser codon introduced into the GPA1 mutant oligo-
nucleotides are shown underlined. The two fragments
were ligated by PCR and cloned into the SacI and
BamHI digested p414GALS as described above. A
ClaI restriction site was also introduced with the
mutation to serve as a diagnostic marker for the
GPA1Ser302Gly mutant.
2.6. Yeast strains
The genotypes of the yeast strains used in this
study are described in Table 1. Yeast strain MMY9
was used as the STE2 strain [40]. The STE2 and
the LYS2 genes of MMY9 were deleted in order to
generate RP2L. Genomic DNA isolated from a
yeast strain containing the integrated kanamycin
resistance gene within its STE2 gene (Research Ge-
netics) served as template to amplify a 2.2-kb frag-
ment containing the ste2v: :G418R allele using the
following forward 5P-GAATTTAAGCAGGCCAA-
CGTCCATAC-3P and reverse 5P-GTGAACATAA-
TATGTGCCTGGTTG-3P oligonucleotides. The pu-
ri¢ed PCR product was used to transform MMY9 to
G418 resistance (200 Wg/ml). Disruption of the STE2
locus in G418R MMY9 transformants was con¢rmed
by PCR using the forward 5P-CTCGTGCATTAA-
GACAGGCTAGTAT-3P and reverse 5P-CTGCAG-
CGAGGAGCCGTAAT-3P oligonucleotides, respec-
tively, corresponding to sequences found in the 5P-
non-coding region of STE2 and in the kanamycin
resistance gene [41]. Disruption of the LYS2 gene
was necessary in order to generate another selectable
marker. The LYS2 disruption construct consisted of
the entire URA3 gene £anked at its 5P- and 3P-ends
by portions of the LYS2 gene. As a ¢rst step both
the URA3 and the LYS2 genes were subcloned into
the polylinker region of pBluescript (pBS). A 1.2-kb
SmaI^ClaI fragment containing the entire URA3
gene was subcloned from Yep24 to give pBS-
URA3, while a 4.6-kb HindIII^PvuII fragment of
LYS2 was subcloned from pDP6 into the HindIII^
SmaI sites of pBluescript to generate pBS-LYS2. Us-
ing the internal BamHI sites within LYS2 and within
the pBluescript polylinker, a 3P 1.1-kb LYS2 frag-
ment was cloned at the 3P-end of the URA3 gene in
pBS-URA3 from pBS-LYS2 to give pBS-URA3-
3PLYS2. A 525-bp 5P-fragment of LYS2 was ampli-
¢ed by PCR using the following forward 5P-
GTCGACTCTAGAGGCATCGCACAGTTTTAG-
CGA-3P and reverse 5P-ATCGATGAACAATAT-
CATCGTCACCGGTTA-3P primers. In this way, a
5P-SalI and a 3P-XbaI restriction sites were intro-
duced which served to clone this fragment 5P to the
URA3 gene in pBS-URA3-3PLYS2. The ¢nal con-
struct, where URA3 is £anked at the 5P- and 3P-
ends by portions of the LYS2 gene was named
pBS-5PLYS2-URA3-3PLYS2. The fragment contain-
ing the LYS2 deletion cassette was puri¢ed and used
to knockout the LYS2 gene. Finally a URA3 gene
having a 242-bp EcoRV^StuI deletion was used to
regenerate the ura3v mutation to make RP2L [32].
Table 1
Description of the yeast strains used in this study
Strain Genotype
MMY9 MATa his3 leu2 trp1 ura3 can1 gpa1v: :ADE2 sst2v: :ura3v far1v: :ura3v fus1: :FUS1-HIS3 LEU2: :FUS1-LacZ
RP2L MATa his3 leu2 trp1 ura3 can1 gpa1v: :ADE2 sst2v: :ura3v far1v: :ura3v fus1: :FUS1-HIS3 LEU2: :FUS1-LacZ
ste2v: :G418R lys2v: :ura3v
BBAMCR 14821 5-2-02
J.L. Kong et al. / Biochimica et Biophysica Acta 1542 (2002) 95^10598
2.7. Yeast growth and transformation
Yeast cells were routinely grown in synthetic me-
dia consisting of yeast nitrogen base containing 2%
glucose (YNBD) and the appropriate nutritional
supplements [42]. Plasmids were introduced into
yeast using lithium acetate essentially as previously
described [43]. The plasmids were selected for and
maintained by omitting the appropriate nutrient
from the growth media (uracil for p426 vectors,
tryptophan for p414-GPA1 and lysine for p427 vec-
tors).
2.8. In vivo L-galactosidase assays
L-Galactosidase activity from the FUS1^LacZ re-
porter gene produced in response to GPCR agonists
was determined by a previously described in vivo
assay using chlorophenol red-L-D-galactopyranoside
(CPRG) as the substrate [32,40]. Brie£y, freshly sat-
urated cultures of the di¡erent yeast transformants
were diluted into fresh YNBD media (OD600 of 0.02)
containing 10 mM aminotriazole, 0.1 M sodium
phosphate pH 7 and 0.1 mg/ml CPRG. The 2-ml
cultures were incubated at 30‡C in 6-well plates for
24 h unless otherwise indicated and the amount of
CPRG cleaved was determined spectrophometrically
at 570 nm.
2.9. Western blot analysis
Soluble protein was extracted by directly boiling
an equal number of NaOH-treated cells (0.1 M,
3 min) in SDS^PAGE loading bu¡er (0.06 M Tris^
HCl pH 6.8, 5% glycerol, 2% SDS, 4% L-mercapto-
ethanol and 0.0025% bromophenol blue) for 3 min
[44]. Protein samples were separated by SDS^PAGE
(12% acrylamide; 37.5 acrylamide: 1 bisacrylamide)
stained with Coomassie blue and protein bands were
quanti¢ed by scanning with an image densitometer
(Multi-Analyst, Bio-Rad). Equal amounts of protein
were then separated by SDS^PAGE, transferred to
nitrocellulose membrane and challenged with anti-
RGS1 antisera (Santa-Cruz Biotech) essentially as
previously described [45]. After washing, the blot
was incubated with an HRP-conjugated donkey
anti-goat IgG antisera and signals were subsequently
developed using chemiluminescent luminol reagent
then exposed to X-ray ¢lm as described by the man-
ufacturer (Santa Cruz Biotechnology).
3. Results and discussion
We have previously demonstrated that mammalian
RGS1, RGS2, RGS5 and RGS16 can functionally
complement yeast cells lacking their endogenous
RGS encoding gene SST2 [33]. In order to further
characterize the function of these RGSs we used a
yeast strain, MMY9, that in addition to lacking
its SST2 gene also contains a FUS1^LacZ reporter
gene integrated into its genome which serves as an
e⁄cient reporter of GPCR activation [40]. Since this
strain lacks a functional GPA1 gene the plasmid
p414GPA1 was used to complement this de¢ciency.
In yeast cells, this plasmid functionally mimics a ge-
nomic copy of the GPA1 gene since it is maintained
at ca. 1 copy/cell by the centromere and the GPA1
gene is expressed under the control of its endogenous
promoter. This is of importance since the level of
Fig. 1. Mammalian RGSs di¡erentially inhibit Ste2p-mediated
activation of a FUS1^LacZ reporter. The yeast strain MMY9
was transformed with p414GPA1 and either plasmid
p426Met25 alone (closed squares) or p426Met25 containing
RGS1 (closed circles), RGS2 (open circles), RGS5 (closed trian-
gles) and RGS16 (open triangles) and were then stimulated
with increasing concentrations of K-factor (from 1039 to 1035
M) for 24 h in media containing the L-galactosidase substrate
CPRG. The amount of CPRG cleaved was determined at 570
nm and re£ects the level of FUS1-mediated activation of the
LacZ reporter gene. Data are mean þ S.D. of triplicate assays
and are typical of four independent experiments.
BBAMCR 14821 5-2-02
J.L. Kong et al. / Biochimica et Biophysica Acta 1542 (2002) 95^105 99
Gpa1p is crucial for normal GPCR-mediated re-
sponses in yeast [32]. The absence of a GPA1 gene
serves to facilitate the expression and evaluation of
di¡erent Gpa1p mutants on GPCR signaling and
RGS function.
3.1. Mammalian RGSs di¡erentially inhibit
Ste2p-mediated signaling
We have used a previously described in vivo yeast
assay to monitor L-galactosidase activity of the
FUS1^LacZ reporter in response to GPCR stimula-
tion [32,40]. L-Galactosidase activity in MMY9 cells
harboring the control plasmid p426MET25 and
p414GPA1 increased in a dose-dependent manner
in response to increasing concentrations of the
Ste2p agonist K-factor (Fig. 1). MMY9 cells harbor-
ing p414GPA1 were also transformed with di¡erent
plasmids expressing RGS1, RGS2, RGS5 or RGS16
under control of the MET25 promoter. While all
four RGSs were able to attenuate the e¡ects of
K-factor, they demonstrated signi¢cant heterogeneity
in their ability to inhibit GPCR response with the
apparent rank order of activity RGS1sRGS16s
RGS2sRGS5 (Fig. 1). These results indicate that
GPCR-mediated activation of the FUS1^LacZ re-
porter serves as a sensitive bioassay for RGS func-
tion.
3.2. Mammalian RGSs completely abolish signaling
from the heterologously expressed somatostatin
receptor 5
Although RGSs are known to block GPCR signal-
ing by limiting the lifetime of the receptor activated
GK-protein, a number of recent reports have impli-
cated the GPCR itself as being a critical component
involved in modulating the speci¢city of the interac-
tion of the di¡erent RGSs with di¡erent GK-subunits
[7,20,21,46,47]. In order to examine the role of the
receptor in modulating RGS function, we expressed
a number of mammalian GPCRs in the Ste2v deriv-
ative of MMY9, RP2L, to assess their ability to ac-
tivate the FUS1^LacZ reporter gene in the absence
of RGSs. RP2L was used for these assays since the
absence of the STE2 gene encoding the K-factor re-
ceptor has been shown to facilitate the functional
expression of heterologous GPCRs in yeast [32,48].
In addition, this strain lacks a functional SST2 gene.
The absence of this gene product has also been
shown to signi¢cantly increase the coupling e⁄ciency
of heterologously expressed GPCRs [31,32]. The in-
dividual RP2L transformants expressing the six dif-
ferent GPCRs were treated with the appropriate re-
ceptor speci¢c ligand; somatostatin 14 for SST5,
Angiotensin II for AT1, isoprotenerol for L2-AR,
prostaglandin F2K for the FP receptor and prosta-
glandin E2 for the both EP3K and EP4K receptors.
Of these, only SST5 and FP2 gave a signi¢cant in-
crease in L-galactosidase activity in ligand-stimulated
cells as compared to the unstimulated controls (Fig.
2). Whereas SST5 has previously been shown to cou-
ple to the yeast Gpa1p GK-protein [32], this is, to our
knowledge, the ¢rst demonstration of the functional
expression of the prostanoid FP receptor in yeast.
SST5 was chosen to assess the ability of RGSs to
inhibit receptor-speci¢c signaling while the character-
ization of the FP receptor in yeast will be described
elsewhere. RP2L cells expressing SST5 responded to
increasing concentrations of somatostatin with a
dose-dependent increase in L-galactosidase activity
(Fig. 3). RP2L transformants expressing SST5 as
well as RGS1, RGS2, RGS5 or RGS16 under the
Fig. 2. Analysis of the expression of mammalian GPCRs in
yeast. The yeast strain RP2L containing p414GPA1 was trans-
formed with p426MET25 plasmids expressing di¡erent mamma-
lian GPCRs and were incubated for 36 h without (3) and with
(+) receptor speci¢c agonists (1036 M) and the level of FUS1^
LacZ response determined. FUS1^LacZ activation without (3)
and with (+) 1036 M K-factor by the endogenous yeast GPCR
(STE2) in strain MMY9 is shown for comparison. Data are
mean þ S.D. of triplicate assays and are typical of three inde-
pendent experiments.
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control of the MET25 promoter were used to assess
the ability of RGSs to inhibit SST5-mediated activa-
tion of the FUS1^LacZ reporter gene. Expression of
any of the four RGSs tested resulted in a complete
abolition of the response to somatostatin (Fig. 3).
RGS2, RGS5 and RGS16 were signi¢cantly more
potent at inhibiting signaling responses from SST5
than Ste2p while RGS1 was equally e¡ective with
both receptors (compare Fig. 2 and Fig. 3) suggest-
ing that SST5 signi¢cantly enhanced the GAP activ-
ity of these RGSs.
It remains possible that the observed e¡ects of
SST5 on RGS function may be due to a receptor-
mediated increase in the level of RGSs in yeast. For
example RGS7 has recently been shown to interact
with the C-terminal intracellular domain of polycys-
tin [9]. Overexpression of the C-terminal domain of
polycystin leads to an increase in the levels of RGS7
due to an increase in its stability. Similarly, stimula-
tion of the Ste2p receptor in yeast leads to an in-
crease in the levels of Sst2p [26,27,49]. Increases in
the half-life of Sst2p as well as in the transcription of
the gene are responsible for the observed up-regula-
tion. An SST5-mediated increase in the transcription
of mammalian RGS genes in yeast is unlikely since
they are expressed under the control of the MET25
promoter which is not responsive to GPCR stimula-
tion. In addition, an SST5-mediated increase in the
stability of mammalian RGSs is unlikely since RGSs
are long-lived proteins in yeast (unpublished). Fi-
nally, Western blot analysis indicated that the levels
of RGS1 do not di¡er in cells expressing Ste2p or
SST5 (Fig. 3, insert). It therefore seems likely that the
increased activity of the RGSs is not due to an SST5-
mediated increase in RGS levels, which suggests that
these RGSs are signi¢cantly more potent at inhibit-
ing SST5- than Ste2p-mediated responses.
3.3. RGSs inhibit SST5-mediated activation of
a Gpa1p/Gi3K transplant
In addition to serving as an activator of heterolo-
gous G-proteins when bound to ligand, the Ste2p
Fig. 4. A Gpa1p/Gi3K chimera increases the e⁄ciency of the
SST5-mediated activation of the FUS1^LacZ reporter. The
yeast strain RP2L containing p426Met25-SST5 was transformed
with p414GPA1 or p414GPA1/Gi3K and was incubated without
(3) or with (+) somatostatin (1036 M) for 36 h to determine
the level of FUS1 LacZ activation. Data are mean þ S.D. of
triplicate assays and are typical of three independent experi-
ments.
Fig. 3. Inhibition of SST5-mediated signaling by RGSs. The
yeast strain RP2L having both p414GPA1 and p426Met25-
SST5 was transformed with the control p427Met25 plasmid
(closed squares) or with the p427Met25 plasmids expressing
RGS1 (closed circles), RGS2 (open circles), RGS5 (closed trian-
gles) or RGS16 (open triangles). The resulting strains were
stimulated with increasing concentrations of somatostatin (from
1039 to 1035 M) for 24 h in media containing the L-galactosi-
dase substrate CPRG. No activity was detectable in response to
somatostatin in cells expressing any of the four RGSs. Data are
mean þ S.D. of triplicate assays and are typical of four inde-
pendent experiments. Insert : Western blot analysis of RGS1 in
cells expressing the endogenous STE2 gene (strain MMY9) and
in cells lacking the STE2 gene (strain RP2L) but expressing
SST5 from p426Met25. Extracts were prepared from exponen-
tially growing cultures of both cells and RGS1 protein was de-
tected as described in the methods section. A single band corre-
sponding to 24 kDa was detected which is in agreement the
calculated 22,431-Da molecular weight of human RGS1. The
band was not detected in cells not expressing RGS1 (not
shown).
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receptor is responsible for maintaining the G-protein
in an inactive form in the absence of ligand [50].
Thus cells lacking a functional Ste2p receptor show
increased basal activation of the G-protein. Given
that RGSs serve to inactivate activated GK-proteins,
it is not surprising that Sst2p assists the Ste2p recep-
tor in preventing basal G-protein activation [51].
SST5 as well as a number of other heterologously
expressed GPCRs can couple to and activate the
yeast GK-protein (Figs. 2 and 3) [31,32]. Neverthe-
less, there is a signi¢cant increase in the basal levels
of FUS1-promoted L-galactosidase activity in cells
that express heterologous GPCRs, such as SST5
compared to yeast cells, that express the yeast
Ste2p receptor (Fig. 2) [32]. This suggests that the
inability to inhibit basal G-protein activation may
be due to the fact that SST5 couples poorly to the
yeast Gpa1p. Therefore, mammalian RGSs may have
an increased ability to inhibit SST5-mediated activa-
tion of Gpa1p due to the weak interaction between
these two proteins. The C-terminal 5 amino acids of
GK-proteins have been shown to play a crucial role in
de¢ning their ability to interact with GPCRs [52].
Replacement of the 5 C-terminal residues of Gpa1p
with the corresponding sequence of a number of
mammalian GK-proteins was shown to increase the
coupling e⁄ciency of a variety of heterologously ex-
pressed GPCRs in yeast [32]. We therefore examined
the ability of SST5 to couple to a yeast/mammalian
Gpa1p/Gi3K transplant mutant. In this chimera, the
C-terminal 5 residues of Gpa1p are with replaced
with the corresponding sequence of Gi3K. Activation
of the FUS1^LacZ reporter in RP2L cells expressing
SST5 in combination with either the GPA1 gene or
with the chimeric GPA1/ Gi3K gene was determined
in the absence of agonist and in response to receptor
stimulation. The basal level of FUS1-promoted L-ga-
lactosidase activity was 5-fold lower in cells express-
ing SST5 and the GPA1/Gi3K transplant compared to
the same cells expressing the GPA1 gene (Fig. 4). The
maximal response to 1036 M somatostatin remained
the same in cells with either GPA1 or with GPA1/
Gi3K (Fig. 4). Nevertheless, the decrease in basal ac-
tivity with the GPA1/Gi3K transplant suggests that
SST5 is more tightly coupled to the G-protein trans-
plant. The observed increase in coupling e⁄ciency
between SST5 and the GPA1/Gi3K transplant is con-
sistent with a recent report by Brown et al. [32].
Stimulation of SST5 in RP2L cells expressing the
Gpa1p/Gi3K transplant gave rise to a dose-dependent
increase in L-galactosidase activity in response to in-
creasing concentrations of somatostatin (Fig. 5). We
then examined the e¡ects of expressing RGS1,
RGS2, RGS5 and RGS16 on the activation of the
FUS1^LacZ reporter by SST5 in combination with
Gpa1p/Gi3K. As observed with Gpa1p (Fig. 3), all
four RGSs inhibited somatostatin-mediated re-
sponses with Gpa1p/Gi3K (Fig. 5), even though the
SST5-mediated activation of the FUS1^LacZ report-
er via the Gpa1p/Gi3K was more e⁄cient. This sug-
gests that the ability of the mammalian RGSs to
inhibit SST5-mediated signaling is not linked to the
strength of the interaction between the GPCR and
the GK-protein.
3.4. SST5-mediated activation of the RGS resistant
GPA1Gly302Ser mutant
Our results suggest that RGS2, RGS5 and RGS16
function as better GAPs for Gpa1p in the presence
of SST5 than in the presence of Ste2p. The possibility
remains that the level of RGS expression achieved in
our cells is insu⁄cient to inhibit Ste2p signaling be-
cause this receptor is signi¢cantly more e⁄cient at
Fig. 5. RGSs inhibit SST5-mediated activation of a Gpa1p/
Gi3K. RP2L cells expressing both SST5 and Gpa1p/Gi3K were
transformed with p427Met25 (closed squares) or with the
p427Met25 plasmids expressing RGS1 (closed circles), RGS2
(open circles), RGS5 (closed triangles) or RGS16 (empty trian-
gles). FUS1 promoter-mediated activation of the LacZ reporter
gene was determined in response to increasing concentrations of
somatostatin. Data are mean þ S.D. of triplicate assays and are
typical of three independent experiments.
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activating the G-protein than SST5. In addition,
since RGSs can directly interact with GPCRs as
well as a number of e¡ector enzymes [7,53], we can-
not rule out the possibility that the observed e¡ects
on SST5 may be due to an interaction between the
RGSs and either the receptor or the e¡ector. This
would in e¡ect prevent the activation of the signaling
cascade. For example, the small RGS, RGS2, has
recently shown to block GsK-mediated signaling not
by acting as a GAP, but by inhibiting the e¡ector
adenylyl cyclase [53]. To address this possibility, we
examined the ability of RGSs to inhibit SST5-medi-
ated activation of the GPA1Gly302Ser mutant. This
mutant has a reduced ability to interact with its cog-
nate RGS protein Sst2p yet it remains a functional
GK-protein [39]. A similar mutation in mammalian
GoK, Gi1K and GqK proteins also reduced their ability
to interact with both mammalian RGS4 and RGS7
[39,54]. This allows GPA1Gly302Ser to be used as a
dominant gain of function mutant that permits us
to monitor the receptor-mediated activation of
Gpa1p in the presence of functional RGS proteins.
In control RP2L cells expressing SST5, the
GPA1Gly302Ser mutant couples to the receptor as ob-
served by the dose-dependent increase in L-galacto-
sidase activity in response to increasing concentra-
tions of somatostatin (Fig. 6). This response was
only partially attenuated by RGS1, RGS2 and
RGS5 (Fig. 6). Similarly, previous studies have
shown that the Ste2p activated GPA1Gly302Ser mutant
is also not completely resistant to the inhibitory ef-
fects of Sst2p [39]. Our results therefore suggest that
SST5 retains its ability to activate GK even in the
presence of functional RGSs. Further, it would ap-
pear that RGSs do not directly interfere with the
ability of SST5 to activate GK.
In contrast to the other RGSs examined, RGS16
prevented somatostatin from mediating the
GPA1Gly302Ser activation of the FUS1^LacZ reporter
gene even at a concentration of agonist as high as
1035 M (Fig. 6). Molecular modeling suggests that
Gly302 of Gpa1p interacts with a highly conserved
Glu residue (Glu83 in RGS4) found within the
RGS box [39,54]. These results suggest that although
the conserved Gly residue of GK and the conserved
Glu residue in the RGS box may be critical for the
interaction of many but not all GK-RGS pairs. The
possibility nevertheless remains that RGS16 directly
interferes with SST5 to prevent its activation of GK.
Alternatively, the fact that all four RGSs are capable
of at least partially inhibiting signaling the
GPA1Gly302Ser mutant suggests the possibility that
mammalian RGSs may serve as e¡ector inhibitors
of some downstream component of the signaling cas-
cade [52]. Direct biochemical analysis would be nec-
essary to further understand the interaction between
the mammalian RGSs and both the wild-type and
mutant Gpa1p [12^14].
In summary, our data suggests that the ability of
an RGS to function as a GAP for a given GK-protein
is strongly dictated by the GPCR involved in activat-
ing the G-protein, which is in agreement with a num-
ber of recent reports, indicating that RGSs may di-
rectly interact with GPCRs [20,21,46,47]. Indeed, the
existence of a trimeric complex between GPCRs, GK-
proteins and RGSs would go a long way towards
explaining the selective functions of the small RGSs
[46].
Although very little is currently known regarding
the molecular determinants involved in mediating the
interaction between GPCR and the small RGSs, the
ability to discriminate between di¡erent GPCRs is
likely to reside within the non-RGS portions of the
Fig. 6. The RGS resistant Gpa1pSer302Gly mutant decreases
RGS-mediated inhibition of SST5 signaling. RP2L cells harbor-
ing plasmids p414GPA1Ser302Gly and p426Met25-SST5 were
transformed with p427Met25 (closed squares) or with the
p427Met25 plasmids expressing RGS1 (closed circles), RGS2
(open circles), RGS5 (closed triangles) or RGS16 (open trian-
gles). SST5-mediated activation in FUS1^LacZ reporter activity
was monitored in response to increasing concentrations of so-
matostatin (from 1039 to 1035 M). Data are mean þ S.D. of
triplicate assays and are typical of three independent experi-
ments.
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small RGSs [5,7]. It is of interest that the C-terminal
tail of the PAF receptor is critical for the ability of
RGS4 to inhibit signaling from this receptor [22].
Our results demonstrate that yeast may serve as a
simple and e⁄cient bioassay in order to elucidate
the molecular determinants involved in modulating
RGS-GPCR selectivity. In fact, we are currently us-
ing conservative segment exchange mutagenesis in
order to identify residues within the non-RGS re-
gions of the di¡erent RGSs that are responsible for
their ability to discriminate between Ste2p and SST5.
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